Press release


26/02/2019
Cost-effectiveness study of dabigatran versus warfarin and rivaroxaban in patients with advanced age and suffering from non-ventricular atrial fibrillation in Spain

1117/5000
BCN HEALTH has published the study "Are cost-effective ACODs in elderly patients? Analysis from the perspective of the National Health System "in the Spanish Journal of Health Economics.
BCN HEALTH developed a cost-effectiveness model to determine the cost to the healthcare system and the effectiveness of dabigatran, warfarin and rivaroxaban for elderly patients (older than 75 years) with non-ventricular atrial fibrillation. In the model, the incremental cost-effectiveness ratio has been used, which is essentially conditioned by the number of clinical events that the patient suffers (stroke, embolism, intracranial hemorrhage and acute myocardial infarction), with its corresponding cost, and by the degree of disability of patients after suffering these events.
The results obtained show that dabigatran is a cost-effective therapy against warfarin and dominant against rivaroxaban, which means that it has lower total costs for the healthcare system and is more effective in relation to the two drugs with which it is compared.
 
 
 
Related links:
 
 
Permalink  
 
Developed by Web4Bio